Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.40 |
| ▸ | FHIT | P49789 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | IRS1 | P35568 | 1/20 | 0.39 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4315953 | 0.81 | ALDH1A1 (0.46) | MAPTALDH1A1GAASMN1; SMN2HPGD | |
| SCHEMBL299130 | 0.81 | ALDH1A1 (0.46) | MAPTALDH1A1GAASMN1; SMN2HPGD | |
| Ethyl Acetate SCHEMBL30749679 | 0.80 | ALDH1A1 (0.45) | MAPTALDH1A1GAASMN1; SMN2HPGD | |
| SCHEMBL4080719 | 0.78 | ALDH1A1 (0.43) | MAPTALDH1A1GAASMN1; SMN2HPGD | |
| SCHEMBL15945408 | 0.78 | GAA (0.50) | MAPTALDH1A1GAASMN1; SMN2HPGD | |
| SCHEMBL24369643 | 0.78 | ALDH1A1 (0.43) | MAPTALDH1A1GAASMN1; SMN2HPGD | |
| SCHEMBL283280 | 0.78 | ALDH1A1 (0.52) | MAPTALDH1A1GAASMN1; SMN2HPGD | |
| SCHEMBL13477788 | 0.76 | GAA (0.44) | MAPTALDH1A1GAASMN1; SMN2HPGD | |
| SCHEMBL2113638 | 0.75 | ALDH1A1 (0.45) | MAPTALDH1A1GAASMN1; SMN2HPGD | |
| SCHEMBL12635484 | 0.75 | ALDH1A1 (0.41) | MAPTALDH1A1GAASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | UCB Biopharma SRL (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-4081296-B1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB Biopharma SRL (BE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4676923-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2025-10-16 | — | — | US | disclosed |
| US-12398130-B2 | Acid addition salts of piperazine derivatives | ASCENEURON SA (CH) | 2025-08-26 | — | — | US | disclosed |
| US-20250136578-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025081092-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-4532496-A1 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2025-04-09 | — | — | EP | disclosed |
| CN-119384420-A | Novel PAR-2 inhibitors | 多曼治疗学公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2024184550-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-09-12 | — | — | WO | disclosed |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| WO-2002015662-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002017358-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002016355-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC) ACETYLCHOLINE RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| EP-0883611-A1 | AZOLYL PIPERAZINYL PHENYL OXAZOLIDINONE ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-16 | — | — | EP | disclosed |
| US-5736545-A | ADMINISTERING TO TREAT BACTERIAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1998-04-07 | — | — | US | disclosed |
| WO-1997030981-A1 | AZOLYL PIPERAZINYL PHENYL OXAZOLIDINONE ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1997-08-28 | — | — | WO | disclosed |
| US-5326776-A | Tetrazoles | ABBOTT LABORATORIES (US) | 1994-07-05 | — | — | US | disclosed |
| WO-1993017681-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136578-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | AR, SHBG, FSHR | MAPT 4567/4885ALDH1A1 1380/4885GAA 4097/4885 |
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | MAPT 3399/4885ALDH1A1 1534/4885GAA 4408/4885 |
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | FCGR2A, FCER2, FCGR1A | MAPT 4836/4885ALDH1A1 2200/4885GAA 3587/4885 |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | NQO2, GBA1, UGT1A1 | MAPT 1250/4885ALDH1A1 130/4885GAA 5/4885 |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PARK7, CYP3A7, UGT2B7 | MAPT 1546/4885ALDH1A1 267/4885GAA 24/4885 |
| US-12398130-B2 | Acid addition salts of piperazine derivatives | DNPEP, GAA, SLC30A5 | MAPT 3165/4885ALDH1A1 63/4885GAA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.